Cabozantinib: as the comparator
7 studies: what is tested is compared with it. Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)RecruitingNCT07227402Phase 3Report a problem
- Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT TrialRecruitingNCT05773274Phase 2Report a problem
- A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid CancerActive, not recruitingNCT04211337Phase 3Results postedReport a problem
- A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)TerminatedNCT03729245Phase 3Results postedReport a problem
- Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell CancerActive, not recruitingNCT05012371Phase 2Report a problem
- A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).WithdrawnNCT04760288Phase 3Report a problem
- A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)Active, not recruitingNCT04586231Phase 3Report a problem